Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Article Abstract:

A drug called STI571 appears to be effective in treating chronic myeloid leukemia. This drug blocks the BCR-ABL tyrosine kinase, which is an abnormal protein produced by the chromosomal abnormality the causes this type of leukemia.

Health aspects, Editorial, Product information, Novartis AG, NVTSY, Gleevec (Medication)

---

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

Article Abstract:

The drug imatinib may be more effective than interferon alfa plus cytarabine for treating chronic myeloid leukemia, according to a study of 1,106 patients. Imatinib was much more effective in lowering blood levels of BCR-ABL, an abnormal protein that causes some of the symptoms of this type of leukemia. Patients whose blood level of BCR-ABL was lowered lived longer free of disease than other patients.

Evaluation, Patient outcomes, Prognosis, Imatinib mesylate

---

Chronic myeloid leukemia -- advances in biology and new approaches to treatment

Article Abstract:

The physiology, genetics, molecular changes, and treatment of chronic myeloid leukemia (CML) are reviewed. CML is caused by a chromosome abnormality called the Philadelphia chromosome that produces an abnormal protein. Treatments include stem cell transplantation and a drug called imatinib.

Care and treatment, Physiological aspects, Genetic aspects

Similar abstracts:

• Abstracts: The natural history of a positive response to transfundal pressure in women at risk for cervical incompetence
• Abstracts: The legacy of Charles Jeffress: one year into the job, the new head of OSHA prepares for his toughest challenges
• Abstracts: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
• Abstracts: Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.